JCM Figure table search 04
Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Laeyendecker, O.
Right arrow Articles by Quinn, T. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Laeyendecker, O.
Right arrow Articles by Quinn, T. C.

 Previous Article  |  Next Article 

Journal of Clinical Microbiology, April 2004, p. 1794-1796, Vol. 42, No. 4
0095-1137/04/$08.00+0     DOI: 10.1128/JCM.42.4.1794-1796.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.

Performance of a Commercial, Type-Specific Enzyme-Linked Immunosorbent Assay for Detection of Herpes Simplex Virus Type 2-Specific Antibodies in Ugandans

Oliver Laeyendecker,1 Charla Henson,2 Ronald H. Gray,3 Ruby H.-N. Nguyen,3 Bobbi Jo Horne,2 Maria J. Wawer,4 David Serwadda,5 Noah Kiwanuka,6 Rhoda Ashley Morrow,7 Wayne Hogrefe,8 and Thomas C. Quinn1,2*

National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda and,1 Department of Medicine, Johns Hopkins University School of Medicine,2 Department of Population and Family Health Sciences, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland,3 Heilbrun Center for Population and Family Health, Joseph L. Mailman School of Public Health, Columbia University, New York, New York,4 Institute of Public Health, Makerere University, Kampala,5 Rakai Project, Uganda Virus Research Institute, Entebbe, Uganda,6 Department of Laboratory Medicine, University of Washington, Seattle, Washington,7 Focus Technologies, Cypress, California8

Received 13 June 2003/ Returned for modification 21 September 2003/ Accepted 7 January 2004

Two hundred forty-eight human immunodeficiency virus (HIV)-positive and 496 HIV-negative subjects in Uganda were tested by HerpeSelect herpes simplex virus type 2 enzyme-linked immunosorbent assay (ELISA) and Western blotting to optimize the ELISA for use in this population. A higher index cutoff value was required for optimal sensitivity and specificity, and overall performance of the assay was not affected by HIV status.

* Corresponding author. Mailing address: Ross Building 1159, 720 Rutland Ave., Baltimore, MD 21205. Phone: (410) 955-3151. Fax: (410) 614-9775. E-mail: tquinn{at}jhmi.edu.

Journal of Clinical Microbiology, April 2004, p. 1794-1796, Vol. 42, No. 4
0095-1137/04/$08.00+0     DOI: 10.1128/JCM.42.4.1794-1796.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:



Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
Antimicrob. Agents Chemother. Clin. Microbiol. Rev.
Clin. Vaccine Immunol. ALL ASM JOURNALS

Copyright © 2004 by the American Society for Microbiology. All rights reserved.